Kiniksa Pharmaceuticals International vs Lakefront Biotherapeutics
KNSA and LKFT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KNSA and LKFT compare
Lakefront Biotherapeutics grew revenue faster over the last twelve months (304% versus 58.2% for Kiniksa Pharmaceuticals International).
Lakefront Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 28.8% compared with 11.6% at Kiniksa Pharmaceuticals International.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 7 for Lakefront Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KNSA | LKFT |
|---|---|---|
| Size and price | ||
| Market cap | $15.1B | – |
| Share price | $96.33 | $33.98 |
| Change, 1 year | 137% | 5.2% |
| Change, 5 years | 690% | −34.0% |
| Beta (5Y) | 0.31 | 0.57 |
| Employees | 366 | 452 |
| StockData Score | ||
| Total score | 14 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 74.1× | – |
| P/S | 16.0× | – |
| P/B | 21.3× | – |
| EV/EBITDA | 110× | – |
| P/FCF | 76.8× | – |
| FCF yield | 1.3% | – |
| Fair value | $17.17 | – |
| Margin of safety | −461% | – |
| Growth | ||
| Revenue growth (TTM) | 58.2% | 304% (better) |
| Revenue growth, 5Y average | – | 18.4% |
| Net income growth (TTM) | 205% | 333% (better) |
| EPS growth (TTM) | 189% | 335% (better) |
| Profitability | ||
| Gross margin | 90.2% | 97.3% (better) |
| Operating margin | 13.8% | 26.5% (better) |
| Net margin | 11.6% | 28.8% (better) |
| FCF margin | 20.8% (better) | −24.4% |
| Return on equity | 17.6% | – |
| Return on invested capital | 60.2% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | 285× |
| Current ratio | 3.91 | 20.15 (better) |
| Altman Z-score | 34.82 | – |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 29.9% | 48.6% |
| Held by insiders | 5.1% | 45.1% |
| Insider net buying, 12 months | −$122M | – |
| Short interest, % of float | 2.9% | – |
Go deeper
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
- LKFT stock overview
- LKFT income statement
- LKFT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.